The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly.
Abstract
We conducted a randomized multicenter trial comparing low-dose cytarabine (LD ARA-C) (20 mg/m2 for 21 days) with an intensive chemotherapy (rubidazone [a daunorubicin-derived agent], 100 mg/m2 for 4 days, ARA-C 200 mg/m2 for 7 days) in 87 patients over 65 years of age with de novo acute nonlymphocytic leukemia (ANLL). Forty-one patients received LD ARA-C and 46 received intensive chemotherapy. The number of complete remissions (CRs) but also of early deaths was higher in the intensive chemotherapy group, while partial remissions (PRs) and failures were more frequent in the LD ARA-C group (P less than .001). Infectious complications during induction treatment were more numerous and more severe in the intensive chemotherapy group (P less than .01). Patients treated with LD ARA-C required fewer RBC transfusions (P less than .02), fewer platelet transfusions (P less than .01), and had a shorter hospital stay for induction treatment (P less than .01). Overall survival and CR duration were not significantly different in either group. In the LD ARA-C group, the survival of patients with PR and those of patients in CRs was identical. We conclude that in a selected group of elderly patients with de novo ANLL a higher number of CRs may be obtained with intensive chemotherapy, but that with LD ARA-C, the number of early deaths is lower, and long-lasting PRs are obtained, resulting in a similar overall survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Löwenberg, B., Zittoun, R., Kerkhofs, H., Jehn, U., Abels, J., Debusscher, L., Cauchie, C., Peetermans, M., Solbu, G., & Suciu, S. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.9.1268 · Cited by 384
Principal results of the Medical Research Council’s 8th acute myeloid leukaemia trial
REES, J. (1986) · The Lancet · doi:10.1016/s0140-6736(86)92674-7 · Cited by 320
Fialkow, P. J., Singer, J. W., Raskind, W. H., Adamson, J. W., Jacobson, R. J., Bernstein, I. D., Dow, L. W., Najfeld, V., & Veith, R. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708203170802 · Cited by 306
Fearon, E. R., Burke, P. J., Schiffer, C. A., Zehnbauer, B. A., & Vogelstein, B. (1986) · New England Journal of Medicine · doi:10.1056/nejm198607033150103 · Cited by 285
Advances in the Treatment of Acute Myelogenous Leukemia
Gale, R. P. (1979) · New England Journal of Medicine · doi:10.1056/nejm197905243002105 · Cited by 213
Cheson, B. D., Jasperse, D. M., Simon, R., & Friedman, M. A. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.12.1857 · Cited by 211
Feldman, A. R., Kessler, L., Myers, M. H., & Naughton, M. D. (1986) · New England Journal of Medicine · doi:10.1056/nejm198611273152206 · Cited by 207
Housset, M., Daniel, M. T., & Degos, L. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb07297.x · Cited by 188
Self-citationResponse of Preleukemic Syndromes to Continuous Infusion of Low-Dose Cytarabine
Wisch, J. S., Griffin, J. D., & Kufe, D. W. (1983) · New England Journal of Medicine · doi:10.1056/nejm198312293092602 · Cited by 178
Kahn, S. B., Begg, C. B., Mazza, J. J., Bennett, J. M., Bonner, H. S., & Glick, J. H. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.8.865 · Cited by 144
Cited by
Juliusson, G., Antunovic, P., Derolf, Å., Lehmann, S., Möllgård, L., Stockelberg, D., Tidefelt, U., Wahlin, A., & Höglund, M. (2009) · Blood · doi:10.1182/blood-2008-07-172007 · Cited by 987
Fenaux, P., Mufti, G. J., Hellström-Lindberg, E., Santini, V., Gattermann, N., Germing, U., Sanz, G., List, A. F., Gore, S., Seymour, J. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.8329 · Cited by 961
Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619
Fehniger, T. A., Uy, G. L., Trinkaus, K., Nelson, A. D., Demland, J., Abboud, C. N., Cashen, A. F., Stockerl-Goldstein, K. E., Westervelt, P., DiPersio, J. F., et al. (2011) · Blood · doi:10.1182/blood-2010-07-297143 · Cited by 107
Sekeres, M. A., Gundacker, H., Lancet, J., Advani, A., Petersdorf, S., Liesveld, J., Mulford, D., Norwood, T., Willman, C. L., Appelbaum, F. R., et al. (2011) · Blood · doi:10.1182/blood-2011-02-337303 · Cited by 80
Metadata
- Authors
- Tilly, H., Castaigne, S., Bordessoule, D., Casassus, P., Le Prisé, P. Y., Tertian, G., Desablens, B., Henry-Amar, M., & Degos, L.
- Venue
- Journal of Clinical Oncology
- Published
- 1990-02
- Volume
- 8
- Issue
- 2
- Pages
- 272-279
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1849389269
- Cited by
- 259
- References
- 15
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. https://app.cochat.ai/papers/10.1200/jco.1990.8.2.272
- The paper
- Tilly, H., Castaigne, S., Bordessoule, D., Casassus, P., Le Prisé, P. Y., Tertian, G., Desablens, B., Henry-Amar, M., & Degos, L. (1990). Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1990.8.2.272
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.